CHISON MEDICAL(SH:688358) Sou Hu Cai Jing·2025-11-25 12:24Core Viewpoint - Xiangsheng Medical (688358) has shown a slight increase in stock price, with a closing price of 31.8 yuan on November 25, 2025, reflecting a 2.12% rise, amidst mixed capital flows from different investor types [1][2]. Financial Performance - For the first three quarters of 2025, Xiangsheng Medical reported a main business revenue of 343 million yuan, a year-on-year decrease of 5.27% [3]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year, while the non-recurring net profit was 86.97 million yuan, a decrease of 2.69% [3]. - In Q3 2025, the company achieved a single-quarter main business revenue of 107 million yuan, down 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [3]. Market Position and Ratios - Xiangsheng Medical's total market capitalization is 3.566 billion yuan, with a net asset value of 1.4 billion yuan [3]. - The company has a price-to-earnings (P/E) ratio of 28.47, which is significantly lower than the industry average of 56.62, indicating a potentially undervalued stock [3]. - The gross margin stands at 59.82%, higher than the industry average of 51.22%, while the net profit margin is 27.37%, compared to the industry average of 9.57% [3]. Investor Sentiment - Over the last 90 days, four institutions have rated Xiangsheng Medical with a "buy" recommendation, indicating positive sentiment among analysts [4]. - On November 25, 2025, the net inflow of main funds was 1.7942 million yuan, accounting for 6.04% of the total transaction amount, while retail investors saw a net inflow of 845,500 yuan, representing 2.85% of the total [1][2].